Dyslipidaemia Management
On this page
Direct answer
Statin intensity is matched to cardiovascular risk, not to a single cholesterol number: established atherosclerotic disease or diabetes with risk factors earns a high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) with low-density lipoprotein commonly targeted below 70 mg/dL, while most primary-prevention patients do well on moderate intensity (atorvastatin 10-20 mg). Fibrates are added only when triglycerides exceed about 500 mg/dL to prevent pancreatitis, and statin-myopathy questions resolve on creatine kinase. Indian patients develop coronary disease a decade earlier and at lower body mass than Western cohorts — the NPCDCS (now subsumed into the NP-NCD framework) screens adults from 30 years. Lifestyle remains the base of every prescription: diet, tobacco cessation, exercise, and control of blood pressure and glucose.
What you must remember
- Statin ladder: moderate intensity — atorvastatin 10-20 mg, rosuvastatin 5-10 mg, simvastatin 20-40 mg (LDL fall 30-49 percent); high intensity — atorvastatin 40-80 mg, rosuvastatin 20-40 mg (LDL fall 50 percent or more).
- Target logic: very-high-risk (recurrent events, multivessel disease) is commonly targeted below 55 mg/dL; high-risk below 70; lower-risk tiers are treated by percentage reduction in most current guidance.
- Statin indications beyond numbers: diabetes mellitus above 40 years with risk factors, chronic kidney disease, prior myocardial infarction or stroke, and familial hypercholesterolaemia (LDL above 190 mg/dL in adults warrants high intensity regardless).
- Triglyceride thresholds: above 150 mg/dL flags metabolic risk; above 500 mg/dL adds a fibrate (fenofibrate 145-200 mg daily) or omega-3 fatty acids specifically to prevent acute pancreatitis.
- Safety monitoring: creatine kinase for muscle symptoms (myopathy, rarely rhabdomyolysis, worse with gemfibrozil or ciclosporin combinations); transaminases at baseline and if symptoms; new-onset diabetes is a small, acceptable statin risk.
- Non-statin layers: ezetimibe 10 mg added when targets are missed; PCSK9 inhibitors for familial hypercholesterolaemia and very-high-risk patients; bempedoic acid as a newer adjunct.
- Secondary causes: hypothyroidism, diabetes, nephrotic syndrome, chronic kidney disease, alcohol and drugs (thiazides, beta-blockers, antiretrovirals, steroids) — check thyroid-stimulating hormone before labelling it primary.
- Indian anchors: premature coronary disease is the subcontinent's epidemic; the national NCD programme screens adults from 30 years at wellness centres, and Indian dietary patterns (refined carbohydrate, trans-fat-rich street food) raise triglycerides as often as cholesterol.
How to work through a lipid clinic case
A 48-year-old man attends after his brother's bypass surgery at 50. He smokes, his blood pressure is 146/88 mmHg on no drugs, LDL is 158 mg/dL, triglycerides 280, high-density lipoprotein 36, and HbA1c is 6.3 percent (prediabetes). Before prescribing anything permanent, exclude secondary causes: thyroid function and urine protein are normal. His risk stratification — smoking, hypertension, prediabetes, strong family history — places him in the high-risk primary-prevention tier, so atorvastatin 20-40 mg daily starts alongside an explicit lifestyle prescription, with a reassessment of lipids and liver profile at six to twelve weeks.
His triglycerides of 280 do not yet justify a fibrate; they justify cutting sugar and alcohol and adding exercise, since the pancreatitis threshold is 500. Six months later, LDL is 88 on atorvastatin 40 mg; his target of under 70 is missed, so ezetimibe 10 mg is added, with his creatine kinase checked first. Compare his diabetic, post-stroke neighbour, who starts at high intensity and is pushed below 70, even towards 55 after a second event: same pharmacy shelf, different arithmetic, and the arithmetic is what the exam tests.
How the FMGE frames it
The examiner asks who gets which intensity of statin far more often than which brand-numbered molecule — expect stems built on combinations (post-MI smoker versus isolated hypertriglyceridaemia) with options graded by intensity. The fibrate question is threshold-based: 500 mg/dL is the pancreatitis trigger, and treating isolated mild hypertriglyceridaemia with fibrates instead of lifestyle is a planted error. Pharmacology one-liners cover myopathy (creatine kinase), the gemfibrozil-statin interaction, and the cytochrome logic that makes simvastatin 80 mg a retired dose. Family-screening hooks appear as familial hypercholesterolaemia — tendon xanthomata, LDL above 190, first-degree screening. The Indian layer is programme-based and increasingly tested: NCD screening under the national programme from 30 years of age, and the observation that Indian risk scores run higher at younger ages and lower BMIs than Framingham cohorts.
Frequently asked questions
Which patients need a high-intensity statin?
Established atherosclerotic disease, LDL above 190 mg/dL, and diabetes above 40 years with additional risk factors — atorvastatin 40-80 mg or rosuvastatin 20-40 mg.
At what triglyceride level is a fibrate added for pancreatitis prevention?
Above approximately 500 mg/dL; lower levels are managed with lifestyle measures and statin-based risk reduction.
How is statin-associated muscle disease evaluated?
Creatine kinase measurement in any patient with new myalgia or weakness, withholding the drug if levels rise substantially or symptoms are severe.
What secondary causes of dyslipidaemia must be excluded?
Hypothyroidism, uncontrolled diabetes, nephrotic syndrome, chronic kidney disease, excessive alcohol and drugs such as thiazides and corticosteroids.
From what age does India's national NCD programme screen adults for cardiovascular risk?
From 30 years, under the programme framework (NPCDCS, now integrated as NP-NCD) at primary health and wellness centres.